Latest Centocor Stories
Lawsuit website reports recent announcement that a California jury has awarded $5.7 million to a woman over J&J Ethicon's Gynecare TVT Abbrevo mesh device. LOS ANGELES, March 11, 2015
AUSTIN, Texas, March 4, 2015 /PRNewswire/ -- XBiotech announced today that results from its Phase II pilot study in patients with moderate to severe plaque psoriasis have been published in JAMA
NEW BRUNSWICK, N.J., March 2, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced a binding offer from Cardinal Health to acquire its Cordis business for an
New Patient Athlete(TM) Program Demonstrates Comprehensive Approach to Driving Sustained Behavior Change and Improved Outcomes NEW BRUNSWICK, N.J., Feb.
NEW BRUNSWICK, N.J., Dec. 30, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 33(rd) Annual JP Morgan Health Care Conference on Monday, Jan.
Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo THOUSAND OAKS, Calif. and LONDON, Nov.
Save the Children named as Enterprise Wide Global Partner NEW BRUNSWICK, N.J., Nov.
Sales of Biologics Will Contribute Approximately $2.3 Billion to the UC Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Brodalumab Meets All Primary and All Key Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, Nov.
Drug Developers will Rely on Head-to-Head Clinical Trial Data Against Current Therapies to be Poised to Compete in the Increasingly Crowded TNF-alpha-Refractory Space BURLINGTON, Mass., Nov.